More Articles

Patients persuade doctors to prescribe brand-name rather than generic drugs Reports | Posted 18/01/2013

Doctors are persuaded by patients to prescribe brand-name drugs when generic drugs are available. That is according to results of a survey carried out by researchers from the Harvard Medical School...

Brand-name and generics labels don’t match Generics/Research | Posted 18/01/2013

According to US federal law generics manufacturers have to have the same labelling as their brand-named counterparts. However, a new study has found that in practice this is often not the case.

Overview of research on analytical techniques in the manufacturing of biosimilars in 2012 Biosimilars/Research | Posted 18/01/2013

Period: January to August 2012 Biologicals are large, complex and heterogeneous proteins with variable molecular weights, typically ranging from 18,000 to 45,000 Da. The active substance of a...

Teva asks FDA to delay approval of Biogen’s MS drug Biosimilars/General | Posted 18/01/2013

Teva Pharmaceutical Industries (Teva) has petitioned FDA not to approve Biogen Idec’s (Biogen’s) investigational pill for treatment of multiple sclerosis, BG-12 (dimethyl fumarate), citing safety c...

Biosimilar trastuzumab made in tobacco plants Biosimilars/News | Posted 18/01/2013

Canada-based PlantForm have altered tobacco plants to create a biosimilar version of Roche’s breast cancer drug Herceptin (trastuzumab).

Watson submits ANDA for generic cancer drug Generics/News | Posted 18/01/2013

Watson Pharmaceuticals confirmed on 28 December 2012 that Actavis, which was acquired by Watson in October 2012, has filed an Abbreviated New Drug Application (ANDA) with FDA seeking approval to ma...

Brand-name drugmaker can be sued for harm caused by generic drug Pharma News | Posted 18/01/2013

On 4 January 2013 the Alabama Supreme Court ruled that Pfizer can be sued for failing to warn about a drug’s risks by a patient who claimed he was injured by a generic version of its gastric reflux...

Generics applications under review by EMA – 2012 Q4 Generics/General | Posted 18/01/2013

Last update:  6 September 2013Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body [1]. Approval by...